Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs CF Industries Holdings, Inc. (CF) Price & Performance

ADMA Biologics Inc
CF Industries Holdings, Inc.

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs CF Industries Holdings, Inc. — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while CF Industries Holdings, Inc. trades at $117.23 (market cap $17.66B). The key difference: CF Industries Holdings, Inc. is far larger — about 8.3× ADMA Biologics Inc's market cap, and CF Industries Holdings, Inc. pays a 1.74% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMACF
Market Cap
$2.13B$17.66B
Sector
HealthBasic Materials
52-Week High
$20.38$137.55
52-Week Low
$7.60$76.08
Enterprise Value
$2.20B$19.24B
Dividend Yield
1.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

CF Industries Holdings, Inc.

CF Industries stock trades at $114.92, up 3.96% today, with a bullish technical signal and strong fundamental metrics including a P/E of 10.2 and net income margin of 23.73%. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $5.71. Recent news highlights robust nitrogen demand and cash flow strength, though rising natural gas costs pose margin pressure.

The outlook remains positive given favorable analyst sentiment, with a consensus price target of $126.67 and 51% buy ratings. Key risks include input cost volatility and geopolitical factors affecting fertilizer markets, but the company's low-cost position and solid balance sheet support continued shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About CF Industries Holdings, Inc.

CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.

Read more on CF